Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452446 | 0.94 | MAPT (0.48) | TLR8MAPTHCAR2ALOX15ELANE | |
| SCHEMBL5462417 | 0.94 | MAPT (0.48) | TLR8MAPTHCAR2ALOX15ELANE | |
| SCHEMBL5459808 | 0.94 | MAPT (0.48) | TLR8MAPTHCAR2ALOX15ELANE | |
| SCHEMBL17082596 | 0.87 | MAPT (0.42) | TLR8MAPTHCAR2ALOX15ELANE | |
| SCHEMBL17082572 | 0.87 | MAPT (0.40) | TLR8MAPTHCAR2ALOX15ELANE | |
| SCHEMBL17082582 | 0.87 | MAPT (0.42) | TLR8MAPTHCAR2ALOX15ELANE | |
| SCHEMBL14645434 | 0.87 | MAPT (0.42) | TLR8MAPTHCAR2ALOX15ELANE | |
| SCHEMBL22282116 | 0.72 | NQO1 (0.37) | SMN1; SMN2 | |
| SCHEMBL5460105 | 0.69 | MAPT (0.40) | TLR8MAPTALOX15SMN1; SMN2 | |
| SCHEMBL5451435 | 0.68 | TLR8 (0.36) | TLR8MAPTHCAR2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
| EP-1385831-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-02-04 | — | — | EP | disclosed |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY (CA) | 2003-08-14 | — | — | US | disclosed |
| WO-2002083651-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | NUDT1, DPYD, TYMP | TLR8 4564/4885MAPT 1146/4885HCAR2 212/4885 |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | TPMT, TYMP, HAVCR2 | TLR8 108/4885MAPT 3202/4885HCAR2 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.